Dr Charlotte Graham Academics Clinical senior lecturer in experimental medicine Contact details charlotte.2.graham@kcl.ac.uk
Immune checkpoint inhibitors therapy for solid organ malignancies after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT Transplant Complications Working Party GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party The impact of ABO compatibility on allogeneic hematopoietic cell transplantation outcomes: a contemporary and comprehensive study from the transplant complications working party of the EBMT Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study: IMMUNOTHERAPY Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee Chemotherapy-induced reversal of ciltacabtagene autoleucel–associated movement and neurocognitive toxicity Four challenges to CAR T cells breaking the glass ceiling Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood Management of complications of chimeric antigen receptor T-cell therapy: a report by the European Society of Blood and Marrow Transplantation Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial Allogeneic car-t cells: More than ease of access? Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies View all publications